Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Cash from Financing Activities (2016 - 2025)

Cytosorbents (CTSO) has disclosed Cash from Financing Activities for 14 consecutive years, with -$1134.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Cash from Financing Activities fell 100.01% year-over-year to -$1134.0, compared with a TTM value of $7.0 million through Sep 2025, down 67.26%, and an annual FY2024 reading of $9.3 million, down 35.54% over the prior year.
  • Cash from Financing Activities was -$1134.0 for Q2 2025 at Cytosorbents, down from $6.8 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $12.2 million in Q4 2023 and bottomed at -$571762.0 in Q1 2024.
  • Average Cash from Financing Activities over 5 years is $2.3 million, with a median of $378211.0 recorded in 2021.
  • The sharpest move saw Cash from Financing Activities soared 6278.64% in 2022, then tumbled 183.56% in 2024.
  • Year by year, Cash from Financing Activities stood at -$80924.0 in 2021, then skyrocketed by 6278.64% to $5.0 million in 2022, then surged by 144.21% to $12.2 million in 2023, then plummeted by 98.63% to $166704.0 in 2024, then plummeted by 100.68% to -$1134.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for CTSO at -$1134.0 in Q2 2025, $6.8 million in Q1 2025, and $166704.0 in Q4 2024.